Lir Bio is building the AI platform that makes it possible — using translational models to discover and develop novel therapies for autism spectrum disorder and related neurodevelopmental disorders.
The biological complexity of ASD has outpaced the tools available to study it. Translation from preclinical models to human outcomes remains a critical bottleneck — until now.
ASD encompasses hundreds of rare genetic variants converging on shared neurobiological pathways — a complexity that conventional phenotype-driven drug discovery cannot adequately model or address.
Animal models capture some aspects of ASD biology but fail to translate predictably to human clinical outcomes. Candidates succeed in preclinical studies only to fail in trials — not because the underlying science was wrong, but because the translation was.
By training models on human multi-omic data and applying them to map biological mechanisms across systems, Lir Bio identifies targets with fundamentally higher confidence of clinical success — bypassing the bottleneck that has defined the field.
Three interconnected capabilities working in concert to compress the timeline from hypothesis to clinical candidate.
Our platform integrates genomic, transcriptomic, proteomic, and epigenomic data from human cohorts and model systems — building a comprehensive biological map of ASD across its full genetic heterogeneity.
Proprietary ML architectures trained to map biological signals between preclinical systems and human biology — dramatically increasing the confidence that a target identified in silico will translate to the clinic.
AI-driven scoring systems evaluate therapeutic target confidence across hundreds of biological criteria, surfacing candidates with the highest probability of clinical success for experimental validation and progression.
Preclinical ASD findings routinely fail to replicate in human trials. Our translational models are designed to address this at its root — not to treat the symptom of a broken pipeline, but to fix the underlying problem.
Lir Bio was founded on a conviction: that autism deserves the full power of modern AI, and that the people living with ASD deserve therapies that actually work.
We named our company after Lir — the ancient Irish deity of the sea, a figure of vast depth, of transformation, and of the unknown that great exploration eventually illuminates. It felt right for what we're building: a platform that charts the unknown biology of autism with new tools and a long view.
Our team brings together computational biologists, machine learning engineers, and clinical neuroscientists united by a shared belief: that a data-driven, translation-first approach is the only path to ASD therapies that succeed where others have failed.
Whether you're a potential collaborator, investor, or research partner, we'd like to hear from you.